Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
| Autor: | Jeffrey A. Bluestone, Jee Hye Kang, Arabella Young |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_treatment Immunology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Tocilizumab Immune system Neoplasms Immunology and Allergy Medicine Humans Adverse effect Immune Checkpoint Inhibitors business.industry Interleukin Cancer medicine.disease 030104 developmental biology Cytokine chemistry Cytokines Secukinumab Tumor necrosis factor alpha Immunotherapy business 030215 immunology |
| Zdroj: | Trends in immunology. 42(4) |
| ISSN: | 1471-4981 |
| Popis: | Cancer immunotherapies can successfully activate immune responses towards certain tumors. However, this can also result in the development of treatment-induced immune-related adverse events (irAEs) in multiple tissues. Growing evidence suggests that cytokine production in response to these therapeutics potentiates the development of irAEs and may have predictive value as biomarkers for irAE occurrence. In addition, therapeutic agents that inhibit cytokine activity can limit the severity of irAEs, and their use is being tested in the clinical setting. This review provides an in-depth analysis of strategies to uncouple the cytokine response, that precipitates irAEs following cancer immunotherapies, from the benefit gained in promoting antitumor immunity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect